German AMNOG reform fails to hit the mark
This article was originally published in Scrip
Reform of Germany's early benefit assessments is currently under discussion, but the change floated looks unlikely to solve any of the main issues that are frustrating companies. During a recent debate in the German parliament, industry made little progress on ensuring that rebates remain confidential, and nothing is likely to change on the thorny issue of comparators, said Dr Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs and Brussels representative for the BPI, which represents small- and medium-sized companies in Germany..
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.